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Antimicrobial resistance to antibiotics is a significant problem in the treatment of serious nosocomial infections. Antibiotic 
therapy is often empiric, until a specific pathogen and its antibiotic susceptibility are known, after which time adjustments 
in initial therapy may be made as necessairy. The increasing prevalence of Gram-positive bacteria as a cause of serious 
nosocornial infections, together with the increasing incidence of resistance among Gram-negative bacilli, require the use 
of compounds with broad-spectrum antimicrobial activity. The third-generation cephalosporins are widely used for empiric 
therapy but their effectiveness has been limited by the increasing prevalence of strains of Enterobacteriaceae and 
Pseudomonas spp. that produce derepressed ArnpC p-lactamases. 
The fourth-generation cephalosporins are structurally related to the third-generation cephalosporins but, in addition, 
they possess a quaternary ammonium group at the C-3’ position. They are zwitterionic compounds, which facilitates rapid 
penetration through the outer membrane of Gram-negative bacteria. This, together with their low affinity for clinically 
important P-lactamases, results in potent activity against many Gram-negative pathogens, including strains producing 
derepressed class I (AmpC) P-lactamase, resistant to most third-generation cephalosporins. In addition, some fourth- 
generation cephalosporins exhibit excellent activity in vitro against Gram-positive bacteria, including methicillin- 
susceptible staphylococci, penicillin-resistamnt pneumococci and viridans group streptococci. 
Among the fourth-generation cephalosporins, only cefpirome and cefepime are widely available. A review of clinical 
studies published to date indicates that they are potentially useful as a first line empiric therapy for serious infections, 
including severe community-acquired and nosocomial pneumonia, bacteremia, febrile episodes in neutropenic patients 
and meningitis. 
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INTRODUCTION 
Antimicrobial resistance t o  currently available 
antibiotics is a significant problem world-wide in the 
treatment of serious nosocomial infections [ 1-31, The 
problem is particularly important with the p-lactam 
antibiotics because of their widespread use [4]. Beta- 
lactamase production is the most prevalent mechanism 
of resistance among Gram-negative bacteria. The 
plasmid-mediated broad-spectrum P-lactamases found 
in Escherichia coli and Klebsiella pneumoniae confer 
resistance to the first-generation cephalosponns [5]. 
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The third-generation cephalosporins were introduced 
in the early 1980s and were poorly hydrolyzed by 
these enzymes, but Gram-negative microorganisms 
resistant to these compounds have emerged [6,7]. 
Until recently, the third-generation cephalosponns 
represented one of the most significant developments 
in the discovery of new p-lactam antibiotics [S]. 
These c e ft r i ax o n e , 
ceftizoxime) possess a C-7 2-amino-5-thiazolyl 
methoximino side chain, which confers greater 
stability against broad-spectrum plasmid-mediated 
P-lactamases. They exhibit enhanced activity against 
Gram-negative bacteria when compared with earlier 
generation cephalosporins [9]. However, the emergence 
of new, extended-spectrum p-lactamases (ESBLs) and 
the prevalence of stably derepresscd mutants of 
ciitcric Gram-ncgative bacilli producing inducible 
chromosomally-mediated class I P-lactamases represent 
c o nip o u n ds ( c e fo taxi m e , 
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a threat to the activity of the third-generation 
cephalosporins [3,10,11]. Some Gram-negative bacilli 
that produce these enzymes, for example Pseudomonas 
aeruginosa and Enterobacter cloacae, also have a less 
permeable outer membrane [6]. 
More recently, Gram-positive bacteria have 
become the predominant cause of serious nosocomial 
infections, particularly bacteremia in neutropenic 
patients and in intensive care units (ICUs) [12-141. 
Current resistance problems among Gram-positive 
bacteria include penicillin and multi-drug resistance 
among pneumococci and viridans group streptococci, 
methicillin resistance in staphylococci and multiple 
drug resistance in enterococci [2,15-171. The 
increasing incidence of Gram-positive pathogens as 
the cause of serious nosocomial infections emphasizes 
the need for compounds with potent, broad-spectrum 
activity against both Gram-positive and Gram- 
negative bacteria, which may be used for empiric 
therapy. Among the p-lactam antibiotics, only the 
carbapenems (imipenem and meropenem) and the 
fourth-generation cephalosporins possess an antibacterial 
activity in vitro that encompasses most Gram-positive 
and Gram-negative bacteria. 
The fourth-generation cephalosporins are chemically 
closely related to third-generation cephems. They 
differ by having a C-3' quaternary ammonium group 
in position 3 of the cephem nucleus. These molecules 
are zwitterionic compounds, by virtue of a positive 
charge on the nitrogen of the C-3' group and a 
negative charge on the C-4 carboxylic group of the 
cephem nucleus [6]. Due to these zwitterionic 
properties they penetrate the outer membrane of 
Gram-negative bacteria rapidly [18,19]. In addtion, 
they have poor affinity for P-lactamases which are 
located in the periplasmic space [18] and, like other 
2-amino-5-thiazolyl derivatives, they have a high 
affinity for penicillin-binding proteins (PBPs) of both 
Gram-negative and Gram-positive bacteria. There are 
two fourth-generation cephalosporins that are currently 
widely available: cefpirome and cefepime [20]. 
ANTIBACTERIAL SPECTRUM 
Cefpirome and cefepime have a well-balanced 
antibacterial spectrum, including Gram-negative 
bacteria as well as Gram-positive cocci. They exhibit 
a greater antibacterial spectrum in vitro than third- 
generation cephalosporins because they are active against 
Enterobacteriaceae which produce class I p-lactamases 
[21-251, which may inactivate third-generation 
cephalosporins. Additionally, they are more active in 
vitro than third-generation cephalosporins against 
Gram-positive cocci, including methicillin-susceptible 
Staphylococcus aureus. Finally, fourth-generation 
cephalosporins, unlike third-generation cephalosporins, 
are active in vitro against Gram-negative bacilli which 
produce derepressed amounts of AmpC P-lactamases 
(3,181. 
The in vitro antibacterial spectrum of the fourth- 
generation cephalosporins includes many of the 
pathogens involved in hospital-acquired infections, 
such as Enterobacteriaceae, P. aeruginosa, Acinetobacter 
spp., Haemopkilus inzuenzae, methicillin-susceptible 
S.  aureus, coagulase-negative staphylococci (CNS), 
pneumococci and viridans streptococci. 
Activity against Gram-positive pathogens 
In a review of the activity of third- and fourth- 
generation cephalosporins, cefpirome was the most 
active agent tested against Gram-positive bacteria 
[23]. In contrast to most of the third-generation 
cephalosporins, cefpirome had good activity in vitro 
against methicillin-susceptible staphylococci. Indeed, 
methicivin-susceptible S. auyeus and CNS were inhibited 
by cefpirome at < 1 mg/L (geometric mean MIC,,) 
(Table 1). This level of activity was two-fold greater 
than that of cefepime, four-fold greater than cefotaxime 
and eight-fold greater than ceftazidime [23]. 
Pneumococci are important pathogens in 
community-acquired pneumonia, meningitis and 
bacteremia/septicemia and the treatment of these 
infections is complicated by an increasing risk of 
encountering penicillin- and multidrug-resistant 
organisms [ 151. The fourth-generation cephalosporins 
demonstrate excellent activity in vitro against 
pneumococci, including penicillin-resistant strains. 
Studies have shown cefpirome and imipenem to be 
the most active p-lactams against Streptococcus pneumoniae 
[15,26,27,28].  I n  o n e  study, cefpirome 
inhibited penicillin-resistant strains with MIC,, and 
MIC90 values of 0.5 and 1 mg/L, respectively, which 
was two-fold superior to cefotaxime and cefepime 
[27]. In another study, cefpirome was more active 
than some of the newer fourth-generation 
cephalosporins, such as cefclidin and cefozopran 
against penicillin-intermediate and penicillin- 
resistant strains (Table 2) [28]. 
Viridans group streptococci are becoming more 
frequent pathogens in the hospital environment, 
particularly in neutropenic and immunocompromised 
patients [29]. The incidence of strains exhibiting 
intermediate- and high-level penicillin resistance is 
increasing, up to 45% of isolates are resistant in certain 
countries [16]. In a study of 410 penicillin-resistant 
viridans group streptococci recovered from blood 
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Table 1 Antimicrobial activity of third- and fourth-generation cephalosporins against micro-organisms involved in serious 
infectionsa 
Organism 
Intrinsic potency (mg/L)b 
Ceftazidime Cefotaxime Cefepime Cefpirome 
S.  aiir~ns 
CNS 
S .  pneumuniae 
Enterococcus spp. 1221 
H .  inflnenzae 
E .  coli 
Klebsivlla spp. 
Entevobacter spp 
C .  frenndii 
Serratia spp. 
Prouidencia spp. 
M .  morganii 
P. aevic@mw 
B. cepacia 
Acinetobacter spp 
8.00 
9.08 
0.27 
>32 
0.06 
0.15 
0.14 
0.52 
0.74 
0.29 
0.17 
0.11 
1.83 
2.30 
3.33 
1.90 
1.54 
0.02 
>32 
0.01 
0.06 
0.01 
0.32 
0.21 
0.50 
0.07 
0.05 
22.6 
6.73 
6.46 
2.10 
1.34 
0.03 
0.06 
0.04 
0.04 
0.06 
0.05 
0.15 
0.04 
0.03 
2.83 
7.13 
1.73 
- 
0.65 
0.50 
0.03 
3.60 
0.06 
0.05 
0.04 
0.07 
0.05 
0.11 
0.08 
0.03 
3.70 
8.00 
0.94 
aAdapted from [23], unless otherwise stated. 
hExpressed as the geometric mean MIC,,, i.e. concentration required to inhibit 50% of organisms. 
Table 2 Activity of third- and fourth-generation cephalosporins against Streptococcus pneumoniae 
Pen-S 
n = 60 
(MIC: < 0.12 nig/L) 
Pen-I Pen-R 
(MIC > 1.0 mg/L) 
n = 60 n = 60 
(MIC 0.12-1 .0 mg/L) 
MICY, MICX, MIC;,, MIC90 
penicillin G 0.03 0.03 0.25 1 .0 2.0 4.0 
cefotaxime 0.03 0.03 0.25 1 .0 1 .0 2.0 
cefpirome 0.01 0.03 0.12 0.5 0.5 1 .o 
cefepime 0.03 0.03 0.25 1 .0 1 .o 2.0 
cefclidin 0.25 0.5 1.0 4.0 8.0 8.0 
cefozopran 0.03 0.06 0.25 1 .0 2.0 2.0 
cefluprenam 0.03 0.03 0.5 1 .0 1 .0 1 .0 
cefoselis 0.03 0.125 0.125 0.5 1 .0 1.0 
Adapted from Frt-maux et al. [28] 
cultures, the activity of cef@ironie (MIC,,, 1 mg/L and 
MIC,,, 4 mg/L) was second only to thalt of imipenem 
[16]. In this study, the MIC,, and MIC,, values for 
cefotaxime were 4 and 8 mg/L, respectively, and MICso 
and MIC,, values for ceftazidime were 2 32 mg/L. 
In contrast to other cephalosporins which are 
inactive, cefpirome exhibits moderate activity in vitro 
against enterococci. In one study, the MIC,, of 
cefpirome for E.  faecalis was 3.6 mg/L [:22]. In another 
study of ICU and hematology isolates, 55% of 
E .  faecalis isolates were inhibited by < 8 mg/L of 
cefpirome [30]. Although this level of activity is 
probably inadequate for the treatment of infections, it 
may be sufficient for the prevention of colonization or 
superinfection, or for the treatment of polymicrobial 
infections which include enterococci. 
Activity against Gram-negative pathogens 
The fourth-generation cephalosporins exhibit similar 
activity in vitro to the third-generation cephalosponns, 
cefotaxime, ceftriaxone and ceftazidime, against 
Enterobacteriaceae which produce non-inducible 
P-lactamases, such as E. coli, Klebsiella spp., Proteus 
mirabilis and Salmonella spp. (Table 1) [23]. Of  greater 
significance is the enhanced activity of fourth- 
generation cephalosporins against Enterobactenaceae and 
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P. amginosa, which produce inducible and derepressed 
AmpC p-lactamases [3,31]. Such p-lactamases confer 
considerable resistance to ceftazidime and other third- 
generation cephalosporins. The incidence of strains 
with AmpC varies geographically and the incidence of 
stably derepressed mutants has increased since the 
widespread introduction of the third-generation 
cephalosporins (Table 3) [32-361. Indeed, in two studies, 
the percentage of derepressed strains of E. cloacae 
increased from 14.4% to 23.6% between 1983 and 
1994, and in P. aeruginosa increased from 5.0% to 9.2% 
during the same period [36]. 
Cefpirome and cefepime display similar activities 
in vitro against Enterobacteriaceae which produce 
inducible and derepressed AmpC p-lactamases [3,37]. 
Of  97 ceftazidime-resistant Enterobacteriaceae (MIC 
> 16 mg/L), 74% of strains were inhibited by 
cefpirome (MIC I 8 mg/L) [24]. In an 11 nation study 
of cefiazidime-resistant Enterobacteriaceae, > 80% of 
strains were inhibited by cefepime (MIC 5 8 mg/L) [37]. 
The  plasmid-mediated, extended-spectrum 
0-lactamases (ESBLs), although clinically less important 
than the chromosomally-mediated Class I p-lactamases, 
are produced by Gram-negative bacteria from patients 
in the ICU and with serious infections [2,5,12]. These 
enzymes are produced by strains of K. pneumoniae and 
E.  coli. Whilst the fourth-generation cephalosporins 
are active against many strains which produce some of 
the ESBLs, they are less active against strains which 
produce TEM-4, SHV-2, SHV-3 and SHV-4 [23,38]. 
The potent in vitro activity of the fourth- 
generation cephalosporins is generally lower against 
non-fermentative Gram-negative bacilli than against 
Enterobacteriaceae. The in vitro activity of cefpirome 
and cefepime is greater than that of cefotaxime against 
P.  aeruginosa, but less than the activity of ceftazidime 
(Table 1) [23]. 
Previous studies have shown that cefpirome and 
cefepime have moderate activity against Peptostreptococcus 
spp. and Fwobacteriwx spp., although the fourth- 
generation cephalosporins have generally demonstrated 
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limited activity against other anerobic Gram-negative 
bacilli such as P-lactamase-producing strains of 
Bacteroidesfvagilis (MIC > 8 mg/L) [39]. 
A major concern is the emergence of strains 
resistant to the fourth-generation cephalosporins; 
Gram-negative bacteria resistant to cefpirome and 
cefepime may be selected in vitro by serial passage 
experiments. However, this is more likely to occur as a 
result of modification of the outer membrane proteins 
than by p-lactamase selection and inactivation [ 11,401. 
Resistance was attributable to derepression of inducible 
chromosomal p-lactamases (although in these 
experiments this was more common with ceftazidime) 
and outer membrane porin changes [40]. The 
cefpirome MICs, although higher, remained below the 
proposed breakpoint of 8 mg/L. The risk of selecting 
resistant strains of Enterobacteriaceae among hospital 
isolates to fourth-generation cephalosporins may be 
lower than for the third-generation cephalosporins in 
the clinical setting, as demonstrated by in vitro studies, 
but more data are necessary [11,40]. 
HUMAN PHARMACOKINETICS AND 
PHARMACODYNAMICS 
The pharmacokinetic properties of cefpirome and 
cefepime have been investigated following intravenous 
(iv) dosing [41,42] (Table 4). Both compounds have an 
elimination half-life ( tyJ  of approximately 2 hours 
[41-431 and this is prolonged in elderly patients 
[42,44,45]. As the pharmacokinetic and 
pharmacodynamic properties of the fourth-generation 
cephalosporins are similar, we chose to present specific 
data on ceEpirome, as follows. In both healthy and 
infected elderly patients, the ce$irome tllz was 1.7 to 2.2 
times longer than in healthy and infected younger 
patients, respectively [44,45]. This also resulted in 
trough concentrations in the elderly that were about 12- 
fold higher than those observed in younger patients 
(Table 5). This slower t y 2  was related to alterations in 
renal function, associated with increasing age [41,44]. 
Table 3 Prevalence of stably derepressed AmpC mutants among Enterobactenaceae and Psetrdomonas aemginosa &om 
1983-1994 
Keference Enterobacteriaceae Enterobacter spp. P .  aemginora 
n % n % n % 
Fuster (1991) ~321 
Liu (1992) 1331 
Goldstein (1993) [34] 
Reeves (1993) [35] 
Lopez-Yeste (1994) [36] 
130 17.0 387 10.8 ND ND 
830 13.2 ND ND 170 1.2 
9038 14.7 348 17.6 ND ND 
ND ND 163 8.7 ND ND 
510 15.1 267 18.7 916 9.2 
ND = No data. 
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Table 4 Pharmacokinetics of cefpirome and cefepime following a 2 g intravenous dose to healthy volunteers 
Parameter Cefpirome Cefepime 
2 g iv 2 g iv 
175 
4.8 
1.9 
130 
70-90 
<10 
133 
4.5 
1.8 
263 
80 
19 
Adapted from [41,42] 
Table 5 Effect of age and infection on the pharmacokinetics of cefpirome 
Status t v z  (h) Trough levels (range) at 12 h (mg/L) 
Age < 50 
Age > 65 
Infection + age < 40 
Infection + age 40-65 
Infection + age > 65 
Age < 40 
1.8-2.0 
3.1-3.4 
2.0 
2.9 
4.4 
2.0 
1.2 (0.25-3.0) 
5.5 (1-13) 
14.2 (2-32) 
Adapted from [41,44,45] 
Following parenteral administration, cefpirome 
distributes primarily into the intravascular compartment 
and potentially therapeutic concentrations are achieved 
in most tissues, including cerebrospinal 5uid (CSF) [41]. 
Cefpirome is extensively excreted via the kidneys and 
the compound has no detectable metabolites [41]. 
For the treatment of serious nosocornial infections, 
the recommended dosage regimen for cefpirome is 2 g 
twice daily (bid). Pharmacodynamic calculations have 
shown that concentrations in serum following 1 g and 
2 g doses of cefpirome are above the MIC for common 
pathogens, including Enterobacteriaceae, staphylococci 
and streptococci, for at least half of the 12-hour dosing 
interval [41]. The time above MIC:,, values for 
common bacterial pathogens following a 2 g dose of 
cefpirome in normal volunteers, are shown in Figure 1. 
Since the MICs for most Enterobacteriaceae, 
staphylococci and streptococci are 1 mg/L or less, 
cefpirome concentrations in serum remain above the 
MIC for these organisms for at least 12 hours. Paradis 
et al. [46] used the serum bactericidal test to demonstrate 
that a 2 g iv dose of cefpirome provided bactericidal 
activity against strains of E. cloacae arid methicillin- 
susceptible S. aureus for more than 12 hours and 8 hours, 
respectively. For P. aevuginosa, the I V I I C ~ ~  value in 
most studies has varied &om 4-1 6 mg/L [22-241. Serum 
concentrations of cefpirome exceed the MIC values 
for only 4.5-8 hours. Therefore, a 2 g dose of cefpirome 
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Figure 1 Relationship between serum levels of cefpirome 
and the MIC,, for common bacterial pathogens following 
a 2 g iv dose. With permission from the Scandinavian 
University Press (411. 
bid may not be adequate for the treatment ofinfections 
caused by P. aeruginosa. 
POTENTIAL CLINICAL INDICATIONS 
A number of studies have demonstrated the efficacy of 
cefpirome and cefepime in the treatment of upper and 
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Table 6 Potential uses and limitations for cefpirome and cefepime 
lower respiratory tract infections, complicated and 
acute uncomplicated urinary tract infections, skin and 
soft tissue and gynecological infections [47,48]. 
However, it is likely that the real place for fourth- 
generation cephalosporins is in the treatment of severe 
hospital- or community-acquired infections (mainly 
pneumonia and bacteremia) and in the treatment of 
febrile episodes in patients with chemotherapy-induced 
neutropenia (Table 6). 
SEVERE INFECTIONS 
Nosocomial and community-acquired pneumonia 
Nosocomial pneumonia represents the  most 
problematic nosocomial infection and may be caused 
by, among others, methicillin-resistant S .  aureus 
(MRSA), Legionella pneumophila, Enterobacteriaceae 
or non-fermentative Gram-negative bacilli. When 
choosing empiric therapy for the treatment of 
nosocomial pneumonia before microbiologcal results 
are available, it is important to consider where the 
infection was contracted. Nosocomial pneumonia 
acquired in the adult or neonatal ICU, burns unit or 
hematology unit is more likely to be associated with 
complicating risk factors than nosocomial pneumonia 
acquired in general medical or surgical wards. Other 
factors, such as the local prevalence of particular 
microorganisms and recent outbreaks, should also be 
taken into account. 
In intubated patients, early-onset pneumonia is 
usually caused by normal inhabitants of  the  
oropharyngeal cavity, such as S. pneumoniae, methicillin- 
susceptible S. aureus and H. injuenzae [49]. In contrast, 
late-onset nosocomial pneumonia is more likely to be 
caused by pathogens such as hospital Enterobacteriaceae 
or P. aeruginosa. Non-fermentative Gram-negative 
bacilli, e.g. Acinetobacter baumannii or Stenotrophomonas 
maltopkilia and MRSA, are encountered in some 
geographic locations [49]. Patients with early-onset 
ventilator-associated pneumonia together with no 
underlying risk factors such as prior antibiotic therapy, 
recent hospitalization, aspiration or a severe underlying 
condition, may be treated initially with agents such as 
p-lactams plus P-lactamase inhibitors, or second- or 
third-generation cephalosporins [50]. For patients 
with late-onset pneumonia, or early-onset pneumonia 
plus associated risk factors, a broader-spectrum 
antibiotic is recommended, such as a fourth-generation 
cephalosporin, a broad-spectrum p-lactam/p-lactamase 
inhibitor with anti-pseudomonal activity such as 
ticarcillin-clavulanate or piperacillin-tazobactam, 
or a parenteral carbapenem. Fourth-generation 
cephalosporins, such as cefpirome or cefepime, may 
be considered as single agent therapy because of their 
high potency against Gram-positive pathogens 
(S .  pneumoniae and S .  aureus) and Gram-negative bacilli 
[2,3,49]. If P. aeruginosa is recovered from the cultures, 
an aminoglycoside or fluoroquinolone should be 
added to fourth-generation cephalosporin therapy. 
The fourth-generation cephalosporins may also be 
considered for the treatment of some cases of severe 
community-acquired pneumonia (CAP), particularly 
in areas with a high incidence of S .  aureus or cases 
where Enterobacteriaceae are suspected (i.e. in chronic 
Category Indications 
Severe infections 
Other severe nosocomial sepsis 
Potential 
Limitations 
Pneumonia 
Nosocomial pneumonia 
Severe conmunity-acquired pneumoniaa 
Neutropenia and fever 
Nosocomial sepsis 
Complicated urinary tract infections 
Intra-abdominal infectionsb 
Polyniicrohial skin and skin structure infectionsC 
Bacterial meningtis 
Anaerobes 
MRSAIMRSE 
ESBL producers 
~~~~ ~ ~ ~ 
aIn areas with a high prevalence of S. aureus community-acquired pneumonia infection (e.g. elderly nursing home patients and following influenza 
outbreaks). 
bIn combination with metronidazole. 
CMixed infections caused by S .  auieus and Gram-negative bacilli. 
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obstructive pulmonary disease (COPD) patients or 
patients with previous courses of antibi'otics) and are 
an alternative to third-generation cephalosporins as 
empiric first-line therapy (Table 6). The predominant 
etiological agents in patients with severe-community- 
acquired pathogens are S. pneumoniae, S .  aureus, H. 
influenme, Moraxella catarrhalis or enceric bacteria 
(especially in COPD patients), which are susceptible to 
ce@irome and cefepime. P. aeruginoso infection is 
rarely encountered except in patients with cystic 
fibrosis, and would not require consideration in other 
patients with community-acquired pneumonia, when 
choosing an empiric regimen. 
The clinical efficacy of cefpirome 2 g bid was 
compared with that of ceftazidime 2 g three times 
daily (tid), in a large randomized multicenter study in 
the treatment of ICU patients with severe pneumonia 
[51]. Pneumonia was hospital-acquired in 75% of 
patients. Patients received monotherapy with either 
cefpirome or ceftazimme, or combination therapy with 
either cephalosporin together with an aininoglycoside 
or nietronidazole, depending on the severity of 
pneumonia. The mean APACHE I1 score was 16, and 
75% and 63% of the patients receiving cefpirome or 
ceftazidime, respectively, were mechanically ventilated. 
A satisfactory clinical response was achieved in 57% of 
evaluable patients and the bacteriological success rate 
was 68% for patients receiving cefpirome or  
ceftazidime. There was no difference in treatment 
outcome between the groups given monotherapy or 
combination therapy. O f  a total of 471 causative 
pathogens isolated from patients (mainly S. aureus, 
H .  inJuerzzae, P.  aeruginosa and S. pneurnoniae), 81.5% 
were susceptible to cefpirome and ceftazidime. 
Cefepime 2 g bid has also been shown to be 
effective in the treatment of severe community-acquired 
or nosocornial pneumonia [52,53]. In a comparative 
study, a satisfactory response was reported in 75% of 
the cefepime patients and 74% of patients receiving 
ceftazidime or cefotaxime 2 g tid [53:1. In  a further 
study of severe community-acquired pneumonia, 
clinical cure rates were 87% in the cefepime group 
and 86% in the ceftazidime group [54]. 
When P. aeruginosa is not the most likely first 
causative agent and in severe cases, a fourth-generation 
cephalosporin is an adequate choice as empiric initial 
monotherapy. However, combination antimicrobial 
therapy should be used when P. aevtrginosa has been 
identified. 
Bacteremiahepticemia 
Morbidity and mortality resulting from bacteremia 
can be a serious problem in the young, the elderly and 
in immunosuppressed and neutropenic individuals. In 
some studies mortality associated with bacteremia has 
ranged from 2&30% of affected patients and more 
than 50% in patients with severe sepsis or septic shock 
[55,56], although mortality is in part due to the 
underlying disease. Prompt recognition of the infection 
and empiric antibiotic treatment are essential before 
the microbiological results are available, to avoid 
complications such as septic shock and multi-system 
organ failure. The predominant microorganisms 
responsible for bacterernia include S .  aureus, CNS, 
Enterococcus spp., S. pneumoniae, viridans group 
streptococci and Enterobacteriaceae (E .  coli, Klebsiella 
spp., Enterobacter spp. and Proteus spp.). P. aeruginosa and 
anaerobes are less frequently encountered. 
Gram-positive cocci have now replaced Gram- 
negative bacilli as the predominant pathogens responsible 
for single-organism bacteremia [ 13,561. Indeed, in the 
EPIIC study (European Prevalence of Infection in 
Intensive Care), 70% of bacteremia/septicemia cases in 
the ICU were caused by Gram-positive species [13]. 
S. aureus is a serious nosocomial pathogen, particularly in 
the ICU where it may cause catheter-related sepsis, 
pneumonia, wound infections and primary bacteremia. 
The management of infections caused by S. aureus is 
further complicated by the relative likelihood of 
encountering methicillin-resistant strains. Therefore, it is 
important to take into account the local prevalence of 
MRSA, as this will dictate the need for vancomycin as 
initial empiric therapy. 
CNS are also a frequent cause of bacteremia. 
However, it is often difficult to assess whether CNS are 
responsible for the infection or whether they are an 
environmental contaminant. The use of intravascular 
catheters in seriously ill patients could account for the 
increase in frequency of CNS as a cause of bacteremia in 
the ICU [13]. The best treatment for these cases is 
uncertain, but removal of the catheter, together with 
antimicrobial therapy, has been recommended by several 
investigators [57]. S. pneumoniae and other streptococci 
are also relatively common causes of bacteremia. 
The aminoglycosides have been widely used for 
empiric therapy of Gram-negative nosocomial 
infections, but have now been replaced with third- 
generation cephalosporins and fluoroquinolones. 
Ceftazidime was used frequently as a first line agent, 
but the emergence of AmpC derepressed mutants of 
Enterobacteriaceae in up to 50%) of strains has diminished 
the utility of third-generation ceplialosporins in the 
ICU (Table 7) [30,36,58,59]. I n  addition, cases of 
progressive sepsis and death caused by penicillin- 
resistant pneumococci in patients treated with 
ceftazidime (ceftazidime MICs of high level penicillin 
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Table 7 Prevalence of stably derepressed AmpC mutants among Enterobacteriaceae and Pseudomonas aerugirrosa of nosocomial 
origin 
Reference 
Number of strains studied (n)/% stable derepressed mutants 
Enterobacter Citrobacter Sewatia M. morganii P .  aemginosa 
n % n %  n % n % n %  
SPP' SPP. SPP. 
ND ND 143 19 Buirma (1991) [58] 105 33 14 7 26 8 
Verbist (1991) 1301 153 37 32 53 ND ND 78 8 326 12 
Syndman (1991) [59] 154 23 48 50 49 6 16 25 177 18 
Lopez-Yeste (1994) [36] 267 25 100 17 45 4 57 0 916 12 
ND = No data. 
resistant pneumococci can be 2 64 mg/L) have been 
reported [26]. 
A fourth-generation cephalosporin, such as 
ceEpirome or cefepime, with activity against Gram- 
positive cocci and Enterobacteriaceae and stability to 
AmpC p-lactamase, may be considered for first-line 
empiric therapy of these infections, before 
microbiological results are available, when infections 
are likely to be polymicrobial or in cases where there 
is no information regarding the strains colonizing the 
patient. In a retrospective analysis of 4,180 patients 
entered in 15 phase I1 and 111 trials [60], the efficacy 
of cefpirome 1 g or 2 g bid was assessed in the treatment 
of confirmed severe bacteremia in patients in ICUs. 
Satisfactory clinical responses were achieved in 97% of 
cefpirome recipients and in 90% of patients treated 
with cefiazidime. Bacteriological eradication occurred 
in 89% of patients treated with cefpirome and in 90% 
of patients treated with cefiazidime. The most common 
pathogens were S. pneumoniae and E. coli, all strains were 
susceptible to cefpirome and cefiazidime. Only four 
out of a total of 230 bacterial isolates were resistant to 
cefpirome, and four out of 60 bacterial isolates were 
resistant to cefiazidime. 
Similar clinical response rates have also been 
obtained in 192 patients with suspected bacteremia 
receiving cefepime 2 g bid (79%) or ceftazidime 2 g 
tid (73%) (611. 
febrile episodes in severe neutropenia 
Gram-positive cocci are the predominant 
microorganisms causing infections in granulocytopenic 
patients. In the Gimema Infection Programme 
conducted in 1991, Gram-negative bacilli were 
responsible for 36% of single-organism bacteremia, 
while Gram-positive cocci accounted for 64% of cases 
[62]. In 1994, the incidence of bacteremia due to 
Gram-positive cocci had risen to 89% [63]. The most 
frequently isolated species were staphylococci, CNS 
(associated with the high use of intravascular catheters 
in these patients) and a-hemolytic streptococci. The 
streptococci were associated with septic shock and 
acute respiratory distress syndrome with up to 45% of 
viridans group streptococci resistant to penicillin 
[15,16]. 
The main Gram-negative bacteria responsible for 
febrile neutropenia infections in cancer patients are 
Enterobacteriaceae and P. aeruginosa, which are ofien 
rapidly fatal. Efforts to reduce this mortality by early 
empiric antimicrobial therapy have been successful, 
but have resulted in significant antibiotic exposure and 
development of bacterial resistance. Ceftazidime has 
been used successfblly as sole therapy, but the emergence 
of strains with derepressed AnipC production together 
with poor Gram-positive coverage has limited its use 
During the last 10 to 20 years, empiric antibiotic 
therapy has been designed for optimal coverage of 
infections caused by Gram-negative bacteria, but with 
the increase in incidence of Gram-positive organisms 
this is no longer satisfactory. Empiric therapy of fever 
in granulocytopenic patients could be achieved using 
a single antibiotic, provided that the compound 
affords adequate coverage against both Gram-negative 
and Gram-positive infections. 
ComGared with the third-generation cephalosporins, 
including ceftazidime, the fourth-generation 
cephalosporins are more active both in vitro and in 
vivo and possess enhanced activity against Gram- 
positive bacteria and Enterobacteriaceae. Accordingly, 
fourth-generation cephalosporins may potentially 
replace cefiazidime for empiric therapy in selected 
patients. The fourth-generation cephalosporin, 
cefepime, has been studied in one open and five 
comparative randomized trials [64]. Overall, 334 
neutropenic patients received cefepime monotherapy 
~ 4 1 .  
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(2 g tid) and 212 received cefepime (2 g bid) in 
combination with amikacin (7.5 mg/kg bid). The results 
showed cefepime monotherapy and combination 
therapy to be as effective as standard regmens of 
ceftazidime monotherapy (2 g tid) or combination 
therapy with broad-spectrum penicillins. In a recent 
multicenter, randomized, comparative study performed 
in 353 patients, the Combination of cefepime plus 
amikacin showed equivalent efficacy to ceftazidime 
plus amikacin in febrile neutropenic patients [65]. 
In an international, multicenter, Ispen labeled, 
randomized trial, a total of 270 neutropenic patients 
were treated empirically with either cee’irome 2 g hid 
or cefiazidime 2 g tid [66]. Positive blood cultures 
were obtained from 41% of cefpironie and 36% of 
cefiazidinie-treated patients, respectively. The clinical 
response rate in both groups was ;’4%, but the 
bacteriological cure rate was higher in the cefpirome 
group (89%) than in the ceftazidime group (74%). The 
predominant causative pathogens in both groups were 
the Gram-positive organisms, S. epidevmidis and 
S .  nureus. Surty-eight percent of patients in the ceEpirome 
group and 65% in the ceftazidime group received at 
least one additional systemic antibiotic at some time, 
either during or at the end of the study. The authors 
concluded that cefpirome 2 g bid was at  least as 
effective and well-tolerated as ceftazidi,me 2 g tid in 
the empiric management of neutropenic patients. 
Bacterial meningitis 
Acute bacterial meningitis is a life-threatening 
infection needing urgent empiric treatment. 
Community-acquired pathogens such as Neisreria 
rneningitidis, H .  influenzae and S .  pneumoniae are the 
predominant causes, accounting for 75% of cases, 
followed by nosocomial pathogens such as Gram- 
negative bacilli, s. atireus and Listeria monorytogenes. 
The emergence of penicillin-resistant and multidrug- 
resistant S. pneumoniae has severely limited the available 
therapeutic options. Recent reports of therapeutic 
failures with some third-generation cephalosporins 
have further complicated the matter [67,68]. Cefpirome 
and cefepime have excellent activiq against these 
organisms in vitro, with the exception of L. monocytogener 
[26,27,69] which, coupled with excellent penetration 
into the CSF in man, offers considerable therapeutic 
potential [70-721. 
In a penicillin-susceptible, pneumococcal meninptis 
model in rabbits, following iv infusion of cefepime 
(25 mg/kg/h) or cefpironie (10 mg/kg/h), antibiotic 
concentrations of 9.6 and 6.6 mg/l,, respectively, 
were achieved in CSF, resulting in 16.2% and 19.3% 
penetration, respectively [73]. In contrast, cefotaxime 
attained a concentration of 2.3 mg/L in the CSF 
following a 50 mg/kg/h iv infusion, representing 4.3% 
penetration. A number of studies have found that the 
MICs and minimum bactericidal concentrations (MBCs) 
of cefpirome for penicillin-resistant pneumococci are 
generally one- to two-fold lower than those for 
cefotaxime, ceftriaxone or cefepime [15,74,75]. 
Although small, such differences may be critical in the 
treatment of meningtis, when the CSF/cephalosporin 
concentration is similar to the MIC. In another animal 
model study [74], the efficacy of several agents was 
compared against pneumococcal infections, involving 
penicillin-sensitive and -resistant strains in rabbits. The 
excellent CSF penetration of cefpironie compared with 
meropenem, rifampicin, clinafloxacin and vancomycin 
was confirmed and cefpirome was more effective than 
meropenem or ceftriaxone. Preliminary results in 
children, using a dose of 50 nig/kg of cefpirome were 
very encouraging. The mean CSF penetration (ratio 
CSF to plasma concentration) was 39% at 2 hours and 
CSF concentrations remained above the MIC,,, of 
common meningeal pathogens (including penicillin- 
resistant pneumococci) for at least 8 hours 1761. Finally, 
in a recent comparative study, cefepime was at  least as 
effective as cefotaxime in the treatment of acute bacterial 
meningitis in children [72]. Additional studies are 
required to support the use of fourth-generation 
cephalosporins in this setting. 
Combination Therapy 
Although the fourth-generation cephalosporins offer 
broad-spectrum activity, they have some deficiencies 
in their antimicrobial spectrum. Methicillin-resistant 
staphylococci and vancomycin-resistant enterococci 
(VKE) pose increasingly serious clinical problems. 
Fourth-generation cephalosporins alone have only 
modest activity against both these organisms. 
Accordingly, if infection? caused by these 
microorganisms are suspected, it is necessary to initiate 
empiric combination therapy with a glycopeptide for 
MRSA. Similarly, if anerobes such as Bactevoidesfva<qilir 
are suspected, then the addition of an anti-anerobe 
agent, such as metronidazole or cliiidamycin, is 
necessary. Fourth-generation cephalosporins should 
be used in Combination with a n  amiiioglycoside or 
fluoroquinolone in most instances of infection caused 
by P. aevuginosa, such as pneunionitis, meningitis or 
bacteremia/septicemia. 
Reassessment of therapy after empiric therapy 
Any empinc treatment must be reassessed at day 2 or 3, 
when the microbiological data and the Initial response 
to therapy are available. Even if initial empiric therapy 
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is effective, based upon results of cultures, antimicrobial 
therapy may be changed to less expensive agents with 
a narrow spectrum of activity. For example, empiric 
therapy with a fourth-generation cephalosporin should 
be switched to an earlier generation cephalosporin if 
E. coli is isolated. Similarly, empiric therapy with a 
fourth-generation cephalosporin plus a glycopeptide 
for a suspected MRSA infection should be changed to 
nafcillin or oxacillin, if methicillin-susceptible 
staphylococci are isolated. Thus, the empiric antibiotic 
therapy must be supported by two complementary 
contracts, the first initially with the patient (i.e. the 
most appropriate antibiotic according to the case and 
the severity) and secondly, 2 to 3 days later with the 
‘community’ (providing antibiotics which have the 
least negative impact upon future potential patients). 
CONCLUSION 
Severe infections, both community-acquired and 
nosocomial continue to be a major problem in hospitals 
with regard to treatment and costs. The incidence of 
nosocomial infection is particularly high in ICUs and 
in neutropenic and other immunocompromised patients 
[13]. These infections are usually severe and are 
associated with high morbidity and mortality. The 
treatment of these serious infections has been 
complicated by the increasing incidence of drug-resistant 
microorganisms, including Gram-positive bacteria. 
Pneumonia is the second most common nosocomial 
infection in the world and is associated with the highest 
mortality and morbidity. The  fourth-generation 
cephalosporins, with their broad antibacterial spectrum, 
would be an attractive therapeutic alternative, 
administered empirically, either as monotherapy or as 
part of a combination regimen. Initial studies utilizing 
fourth-generation cephalosporins in patients suffering 
from severe nosocomial pneumonia in the ICU are 
encouraging [52,53]. Cefpirome is one of the most 
potent p-lactam antibiotics against penicillin-resistant 
pneumococci and staphylococci [15,26,27,74] and 
should be usefd for the treatment of hospitalized patients 
with severe, community-acquired pneumonia or early- 
onset nosocomial pneumonia. 
In neutropenic patients receiving cancer 
chemotherapy, mortality is significantly reduced by 
empiric treatment with broad-spectrum agents or by 
combination therapy, at the onset of infection [77]. In 
this setting ceftazidime, imipenem/cilastatin and 
meropenem have been successfully used as monotherapy 
in febrile neutropenic patients over the last decade 
[65,78,79]. The increasing prevalence of Gram-positive 
pathogens, including CNS, S. aureus and viridans 
streptococci, emphasizes the persistent need for new 
agents with potent activity against both Gram-positive 
and Gram-negative bacteria. The broad-spectrum 
activity of cefpirome and cefepime indicates that they 
could be useful for empiric treatment of febrile 
episodes in neutropenic patients, either alone or in 
combination. Initial studies have shown encouraging 
results when compared to ceftazidime [49, 62-66]. 
Thus, cefpirome and cefepime, with their broad- 
spectrum activity, are valuable additions to the treatment 
of severe infections in hospitalized patients. Further 
comparative studies are required to establish the true 
value of the fourth-generation cephalosporins in the 
treatment of serious nosocomial infection and to 
determine whether they induce less selective pressure 
upon Gram-negative hospital strains. 
DISCUSSION 
Prof. W. Wilson: There has been a lot of discussion 
about the use of fourth-generation cephalosporins 
such as cefpirome in the treatment of patients with 
severe CAP. There are geographic differences with 
respect to the spectrum of microorganisms recovered 
from severe CAP. In the USA, S. aureus is the second 
most common cause of severe CAP after S .  pnarrnoniae, 
in elderly nursing home patients or patients who are 
post influenza with a secondary bacterial infection. In 
this setting, cefpirome would be a good choice for 
empiric therapy, before the microbiological results 
become available. 
Prof. J. Garau: Cefpirome exhibits good in vitro 
activity against methicillin-susceptible S. aureuj. In 
Spain, however, S .  aureus as a cause of primary CAP 
is uncommon. However, in areas with a high 
incidence of S .  aureus pneumonia, fourth-generation 
cephalosporins would be an alternative to the third- 
generation cephalosporins. 
For the treatment of nosocomial pneumonia, 
when P. aeruginosa infection is indicated, then ce@irome 
would not be considered for first-line empiric therapy. 
P. aeruginosa pneumonia is mainly seen in the ICU, 
therefore for nosocomial pneumonia outside of the 
ICU, fourth-generation cephalosporins could be 
considered for empiric therapy. 
Prof. K. Klugman: Cefpirome has a good 
theoretical indication in the treatment of meningitis, 
and it could become the drug of choice, however 
clinical data are needed to support this. In a CSF 
penetration study, cefpirome showed excellent 
penetration in children (analogous to the rabbits). 
However, this study was only performed in a limited 
number of children. 
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Prof. J. Garau: Was a 50 mg/kg dose used? 
Prof. K. Klugman: I believe so. There was some 
reluctance to proceed with the study because of the 
potential for seizures. Some of the children had seizures 
before they received the drug, indeed, 10-20% of 
children with meningitis have seizures without 
antibiotic therapy. Therefore, there is no evidence 
that the drug was related to seizures. The mean CSF 
penetration ofcefpirome in children was > 10-15 mg/L. 
Prof. B. Wiedemann: Are there any data on the in 
vitro activity of cefpironie against ceftriaxone-resistant 
S. pneumoniae? 
Prof. K. Klugman: Yes, there are somc unpublished 
data. Approximately 40% of penicillin-resistant 
pneumococci exhibit MIC values to cefotaxime or 
cefiriaxone 2 1 mg/L, and 8% exhibit MICs to 
cefpirome of 1 mg/L. None of strains tested exhibited 
MICs to cefpirome > 1 mg/L. In terms of the current 
NCCLS breakpoints no strains were resistant to 
cefpirome i.e. MICs > 1 mg/L. For cefpirome, the 
CSF penetration is approximately 15 mg/L, and using 
a maximum MIC of 1 mg/L pharmacodynamic 
calculations would predict that for tid dosing, the 
MIC would be exceeded for the whole dosing 
interval in CSF. 
Prof. B. Wiedemann: Would this concentration be 
sufficient to exhibit a killing/bactericidal effect? 
Prof. K. Klugman: Yes, we would predict that. 
Prof. A. Bryskier: Is there any difference between 
the PBP affinity for cefpirome, cefotaxime and 
ceftriaxone in S .  pneumoniae? 
Prof. K. Klugman: To my knowledge there are no 
studies that have specifically looked at );he affinity for 
PBPs. However, differences in the binding affinities 
could explain the improvement in in v:itro potency. 
Prof. J. Garau: Professor Klugman, are there data 
comparing the bactericidal activity of ceftriaxone, 
cefotaxime and cefpirome? 
Prof. K. Klugman: Yes, cefpimme is highly 
bactericidal. 
Prof. J. Garau: Is cefpirome more ba.ctericida1 than 
the other cephalosporins, as they are less bactericidal 
than penicillin? 
Prof. K. Mugman: Yes, at comparative concentrations 
cefpirome is more bactericidal. Synergy with 
vanconiycin has also been demonstratcd in time-kill 
studies. 
Prof. J. Garau: Are there any data regarding the activity 
of cefpirome against cefotaxime-resistant pneumococci 
(MICs of 16-32 mg/L), described in the USA? 
Prof. K. Klugman: These strains have currently only 
been described in Tennessee, however they may pose 
a problem in the future. 
Prof. R. Jones: In the geographic areas where there 
is a high incidence of penicillin-intermediate and 
particularly penicillin-resistant pneuniococci, the 
fourth-generation cephalosporins, like cefpirome, 
could have a significant role in the treatment of CAP. 
Prof. J. Garau: There is no clinical data to support 
the use of fourth-generation cephalosporins rather 
than the third-generation cephalosporins. It would be 
difficult to justify a fourth-generation cephalosporin 
for CAP. In Spain, 40% of cases of pneumococcal 
pneumonia are caused by penicillin-resistant strains, 
and these are still treated with cefotaxime, even if the 
cefotaxime MIC is 2 mg/L. It would be difficult to 
justifji fourth-generation cephalosporins for CAP based 
on in vitro activity alone. The main advantage of 
cefpirome over the third-generation cephalosponns is 
activity against S .  aureus. This would not be achieved 
with cefotaxime, unless using a high dosing regimen. 
Prof. R. Jones: Among the methicillin-susceptible 
staphylococci, cefotaxime and ceftriaxone exhibit an 
MIC,, of 2 mg/L, and well over 98-99% of strains 
exhibit MICs 5 8 mg/L. In a comparative study 
conducted in the USA, there was a four-fold potency 
advantage for cefpirome against staphylococci, however 
the absolute number and percentage of susceptible 
strains was essentially the same as for the third-generation 
cephalosporins. A similar potency advantage would be 
observed for cefpirome against pneuniococci. Current 
doses of third-generation cephalosporins are being 
increased to cover the more resistant endemic strains. 
An alternative to coiisider could be the fourth- 
generation cephalosporins, because of a two-fold or 
four-fold advantage against pneumococci. 
Prof. J. Garau: However, penicillin is still used for 
the treatment of penicillin-resistant pneumococcal 
infection, except in the case of meninatis. 
Prof. K. Klugman: It would be difficult to 
extrapolate arguments for the treatment of meninatis 
to pneumonia, as the third-generation cephalosporins 
reach peak serum concentrations of 100 nig/L, with 
concentrations remaining above the MIC for the 
entire dosing interval. There is no objective evidence 
that third-generation cephalosporins are not effective 
for the treatment of pneumococcal pneumonia. 
Indeed, the data suggests that penicillin is still effective 
for the treatment of pneumococcal pneumonia. 
Prof. R. Jones: I agree, routine doses of third- 
generation cephalosporins are still utkzed in the USA for 
the treatment of pneumococcal pneumonia. In 1995, 
for a period of time, over 50% of strains in hospitalized 
patients with significant invasive pneumococcal 
disease (meningitis or pneumonia with bacteremia) were 
caused by non-susceptible pneuniococci. I n  all cases, 
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a clinical response was obtained with third-generation 
cephalosporins at modest normal dosing for 
pneumococcal pneumonia. However, there are potency 
advantages for the fourth-generation cephalosporins 
and they should be considered for wider use. 
Dr. J. Turnidge: On pharmacodynamic grounds, 
conventional doses of cefotaxime alone should 
susciently cover S .  aureus and most strains of 
penicillin-intermediate and -resistant pneumococci. A 
fourth-generation cephalosporin may not be necessary 
to cover the current resistance levels. 
Prof. M. Glauser: Professor Garau, can you discuss 
when cefpirome could be used as monotherapy, or 
when it should be used in combination? 
Prof. J. Garau: It would not be advisable to use 
combination therapy initially, unless P. aeruginosa 
infection is indicated. If P. aeruginosa was the most 
likely pathogen, then a more potent antipseudomonal 
agent combined with an aminoglycoside or ciprofloxacin 
is recommended. 
Prof. M. Glauser: Would you consider cefpirome 
for monotherapy in all the indications mentioned, except 
for documented infections caused by P. aeruginosa? 
Prof. J. Garau: Yes, and for intra-abdominal infections 
caused by a mixture of aerobes and anerobes, 
combination therapy would be used to expand the 
spectrum of activity. When combination therapy is 
used to enhance the bactericidal activity, by the 
addition of an aminoglycoside or a fluoroquinolone to 
the regimen, I would recommend cefiazidime or 
another more potent antipseudomonal agent plus an 
aminoglycoside, against P.  aeruginosa infection. 
However, if cefpirome was the initial empiric therapy 
for nosocomial pneumonia in the ICU, and the 
microbiological results confirmed that P. aeruginosa 
had been identified and was susceptible to cefpirome, 
I would continue therapy with cefpirome in 
combination with an aminoglycoside. 
Professor Bryskier, which drug would you 
recommend ifboth cefpirome and ceftazidime exhibited 
an MIC value against P. aeruginosa of 1 mg/L? 
Prof. A. Bryskier: There is often a wide variation in 
the susceptibility of P. aeruginosa, on one culture they 
exhibit MIC values of 1 mg/L and on retesting exhibit 
MICs of 4 mg/L. In France, combination therapy with 
a p-lactam plus an aminoglycoside for at  least three 
weeks is recommended for the therapy of Pseudomonas 
infections. Monotherapy for the treatment of 
Pseudomonas infections is not recommended. 
Ceftazidime is a dianionic compound and if the 
inoculum level is increased it does not exhibit 
bactericidal activity. In contrast, cefpirome is a 
zwitterionic compound and exhibits bactericidal activity 
if the inoculum is increased. The same principle also 
applies to cefepime. Therefore, the quaternary 
ammonium cephems would have an advantage over 
ceftazidime. 
Prof. J. Garau: If a patient has a P. aeruginosa infection 
with a low cefpirome MIC, then combination therapy 
with an aminoglycoside could be considered. 
Prof. W. Wilson: For most infections caused by 
Pseudomonas, combination therapy would be 
recommended, although there are some infections 
where combination therapy would not be necessary. 
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